阅读说明：本技术 分离的赤红球菌细胞壁骨架在制备治疗人***瘤病毒感染的药物中的用途 (Use of isolated Rhodococcus ruber cell wall scaffolds in the preparation of a medicament for the treatment of human papillomavirus infection ) 是由 盖波 窦春艳 张轶 张国英 于 2019-12-24 设计创作，主要内容包括：分离的赤红球菌细胞壁骨架或包含其的组合物在制备治疗人乳头瘤病毒感染的药物中的用途。该赤红球菌骨架从2019年03月22日保藏在北京市朝阳区北辰西路1号院3号的中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC 17431的赤红球菌中分离获得。(Use of an isolated Rhodococcus ruber cell wall scaffold or a composition comprising the same in the manufacture of a medicament for the treatment of human papillomavirus infection. The Rhodococcus ruber skeleton is separated and obtained from Rhodococcus ruber which is preserved in China general microbiological culture Collection center of China Committee for culture Collection, China Union 1, No. 3, Kyoho, Beijing, on the market for 03 and 22 days in 2019 and has the preservation number of CGMCC 17431.)

Use of an isolated Rhodococcus ruber (Rhodococcus ruber) cell wall scaffold in the preparation of a medicament for the treatment of human papillomavirus infection, wherein:

preferably, the isolated Rhodococcus ruber cell wall skeleton is derived from Rhodococcus ruber with the collection number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China Committee No. 3 of Xilu No.1 on North Cheng, Kyoho, Beijing, 03 and 22 days in 2019.

The use according to claim 1, wherein the isolated Rhodococcus ruber cell wall skeleton is obtained by:

1) providing Rhodococcus ruber;

2) culturing said Rhodococcus ruber;

3) collecting the cultured Rhodococcus ruber;

4) pulverizing the cultured Rhodococcus ruber to obtain a pulverized product; and

5) removing lipid, nucleic acid and protein from the obtained pulverized product.

Use of a pharmaceutical composition for the manufacture of a medicament for the treatment of human papillomavirus infection, wherein the pharmaceutical composition comprises:

an isolated Rhodococcus ruber cell wall skeleton, preferably derived from Rhodococcus ruber with the collection number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China Committee for culture Collection of microorganisms No. 3 of Navy No.1, North Cheng, Kyoho, Beijing, in 2019, 03 and 22 days; and

a pharmaceutically acceptable excipient;

preferably, wherein the isolated Rhodococcus ruber cell wall skeleton is 1 part by weight and the pharmaceutically acceptable excipient is 200 to 300 parts by weight;

preferably, the pharmaceutically acceptable excipient is 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 and any point within any two numerical ranges.

The use according to claim 3, wherein the pharmaceutically acceptable excipient is selected from the group consisting of dextran, trehalose, glycine, xylitol, sodium carboxymethylcellulose, erythritol, gelatin, magnesium stearate and mannitol.

The use according to any one of claims 1-4, wherein the medicament is for topical administration, preferably the topical administration is a dermal or mucosal coating, or a dermal or submucosal injection.

The use according to claim 5, wherein the medicament is formulated as an ointment, cream, plaster, gel, lotion, tincture, liniment, oil, paste, lyophilized powder, aerosol, suppository, patch or suspension, preferably wherein the medicament is formulated as a lyophilized powder formulation and the lyophilized powder formulation is diluted in physiological saline prior to use to a concentration of the Rhodococcus ruber cell wall skeleton of 15 μ g/ml to 500 μ g/ml, preferably a concentration of 30 to 240 μ g/ml, more preferably a concentration of 30 to 120 μ g/ml, more preferably a concentration of 30 to 60 μ g/ml.

Use of an isolated Rhodococcus ruber cell wall scaffold in the manufacture of a medical device for the treatment of human papillomavirus infection, wherein:

preferably, the isolated Rhodococcus ruber cell wall skeleton is derived from Rhodococcus ruber with the preservation number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China Committee No. 3 of Navy No.1, Kyoho, Beijing, on 2019 for 03 and 22 months;

said medical device comprising said isolated Rhodococcus ruber cell wall skeleton, and

optionally, a pharmaceutically acceptable excipient.

Use according to claim 7, wherein the medical device is an external medical device, preferably selected from the following forms: a dressing, patch, bandage or film, preferably impregnated with a suspension comprising the cell wall skeleton of Rhodococcus ruber at a concentration of from 15 μ g/ml to 500 μ g/ml, preferably at a concentration of from 30 to 240 μ g/ml, more preferably at a concentration of from 30 to 120 μ g/ml, more preferably at a concentration of from 30 to 60 μ g/ml.

The use according to any one of claims 1-8, wherein the human papillomavirus infection is selected from the group consisting of human papillomavirus infections of the skin, cervix, vagina, labia, penis, anal perianal, oropharynx, tonsils, and oral cavity.

An isolated Rhodococcus ruber cell wall scaffold for use in the treatment of human papillomavirus infection, wherein:

preferably, the isolated Rhodococcus ruber cell wall skeleton is derived from Rhodococcus ruber with the collection number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China Committee No. 3 of Xilu No.1 on North Cheng, Kyoho, Beijing, 03 and 22 days in 2019.

A pharmaceutical composition for use in the treatment of human papillomavirus infection, wherein the pharmaceutical composition comprises:

an isolated Rhodococcus ruber cell wall skeleton, preferably, the isolated Rhodococcus ruber cell wall is derived from Rhodococcus ruber with the preservation number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China institute of culture Collection of microorganisms No.1, Navy, No. 3, Kyowa, Kyoho, Beijing, in 2019, 03 and 22 days; and

a pharmaceutically acceptable excipient;

preferably, wherein the isolated Rhodococcus ruber cell wall skeleton is 1 part by weight and the pharmaceutically acceptable excipient is 200 to 300 parts by weight;

preferably, wherein the isolated Rhodococcus ruber cell wall skeleton is 1 part by weight, the pharmaceutically acceptable excipient is 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 and any point value within any two numerical ranges.

The isolated Rhodococcus ruber cell wall skeleton for use in the treatment of human papillomavirus infection according to claim 10, or the pharmaceutical composition for use in the treatment of human papillomavirus infection according to claim 11, wherein the isolated Rhodococcus ruber cell wall skeleton is obtained by:

1) providing Rhodococcus ruber;

2) culturing said Rhodococcus ruber;

3) collecting the cultured Rhodococcus ruber;

4) pulverizing the cultured Rhodococcus ruber to obtain a pulverized product; and

5) removing lipid, nucleic acid and protein from the obtained pulverized product.

A method of treating a human papillomavirus infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated rhodococcus ruber cell wall scaffold or a pharmaceutical composition comprising the isolated rhodococcus ruber cell wall scaffold, wherein:

preferably, the isolated Rhodococcus ruber cell wall skeleton is derived from Rhodococcus ruber with the preservation number of CGMCC17431, which is deposited in China general microbiological culture Collection center of China Committee No. 3 of Navy No.1, Kyoho, Beijing, on 2019 for 03 and 22 months; preferably, the administration is topical administration; preferably, the topical application is a dermal or mucosal coating, or a dermal or submucosal injection.

The method of claim 13, wherein the therapeutically effective amount of the unit dose is from 1 μ g to 1000 μ g; preferably, 15 μ g to 500 μ g, preferably 30 to 240 μ g, more preferably 30 to 120 μ g, more preferably 30 to 60 μ g;

preferably, the treatment is performed at a frequency selected from the group consisting of: 1 to 3 administrations a day, 1 to 6 administrations a day, 1 to 9 administrations a three day, 1 to 14 administrations a week, 1 to 60 administrations a month; more preferably, 1 administration per day;

preferably, the treatment lasts from 2 days to 2 months, more preferably for 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks.